Magstim has announced the FDA has issued 510(k) clearance of its Horizon Performance TMS therapy system and is making it immediately available for sale in the US.

The product also recently received a CE mark.

Dr Andrew Leuchter, Professor of Psychiatry and Director of the Neuromodulation Division at the Semel Institute of Neuroscience and Human Behavior at UCLA, said “It is exciting to see continued product development and innovation in TMS technology. Magstim’s Horizon Performance system has a number of features that have great potential to benefit patients. The flexibility of this new device to deliver stimulation at a wide range of frequencies and intensities make it a very attractive system for clinicians as well as researchers.”